home / stock / cmxhf / cmxhf news


CMXHF News and Press, Csl Ltd From 02/13/24

Stock Information

Company Name: Csl Ltd
Stock Symbol: CMXHF
Market: OTC

Menu

CMXHF CMXHF Quote CMXHF Short CMXHF News CMXHF Articles CMXHF Message Board
Get CMXHF Alerts

News, Short Squeeze, Breakout and More Instantly...

CMXHF - CSL Ltd (CSLLY) Q2 2024 Earnings Call Transcript

2024-02-13 00:53:08 ET CSL Ltd (CSLLY) Q2 2024 Earnings Conference Call February 12, 2024, 19:00 ET Company Participants Mark Dehring - Head, IR Paul McKenzie - MD, CEO & Executive Director William Mezzanotte - EVP & Head, Research and Development Her...

CMXHF - CSL Limited falls after Phase 3 setback for key trial

2024-02-12 13:53:40 ET More on CSL CSL Limited: Positive Capital Return And Earnings Growth Expectations Arcturus, CSL win approval for world’s first self-amplifying mRNA vaccine in Japan Historical earnings data for CSL Dividend scorecard for CSL ...

CMXHF - Arcturus: H1 2024 Rare Disease Drug Data On Deck

2024-01-31 17:20:05 ET Summary Arcturus Therapeutics Holdings Inc. interim results from the phase 1b study, using ARCT-032 for the treatment of patients with Cystic Fibrosis, are expected in the 1st half of 2024. The global Cystic Fibrosis market is projected to grow to $12.9 bill...

CMXHF - Masking returns to some U.S. hospitals amid rising COVID, flu cases

2024-01-04 13:51:02 ET More on BioNTech, Moderna, etc. Pfizer: If You Missed The Pandemic Entry, Here's Another Chance BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovatio...

CMXHF - Pneumonia outbreak in China is no reason for alarm: WHO

2023-11-24 12:35:42 ET More on BioNTech, GSK, etc. BioNTech Vs. Moderna: Navigating The mRNA Landscape Pfizer Is A Fantastic Buy And So Are These 9%-Yielding Blue Chips Moderna Nears Key Technical Level With Indications Of Reversal (Rating Upgrade) GSK makes ...

CMXHF - Concurrent use of COVID and flu shots is linked to stroke risk in older adults

2023-10-26 10:53:55 ET More on BioNTech, GSK, etc. Pfizer: Ignore The Noise And Buy This Deep Value Seagen's Acquisition: EU Approval And Potential Upside Pfizer: Huge Upside Potential And 5%+ Yield Pfizer, BioNTech post early-stage data for COVID-flu combo s...

CMXHF - The 'tripledemic' threat to be less severe this season

2023-09-17 12:00:54 ET The impact of COVID, flu, and RSV on U.S. and U.K. hospitals is expected to be lower this winter compared to last, as there won't be a significant overlap between peak outbreaks of infections, the London-based data analytics firm Airfinity said in a recent report. ...

CMXHF - Arcturus, CSL granted EU review for COVID vaccine

2023-09-05 10:13:43 ET More on Arcturus, CSL, etc. CSL: Watch Out For Positive Surprises CSL Limited ( OTCQX:CSLLY ) Q4 2023 Earnings Call Transcript CSL Limited 2023 Q4 - Results - Earnings Call Presentation Arcturus Therapeutics Holdings Inc. ( ARCT...

CMXHF - CSL Limited (CSLLY) Q4 2023 Earnings Call Transcript

2023-08-15 02:37:06 ET CSL Limited (CSLLY) Q4 2023 Earnings Conference Call August 14, 2023 09:00 PM ET Company Participants Mark Dehring - Head of Investor Relations Paul McKenzie - Chief Executive Officer Joy Linton - Chief Financial Officer Bill Campbell -...

CMXHF - Starpharma: Patience Needed, But A Lot To Like

2023-07-27 09:40:36 ET Summary The news on Starpharma share price is challenging as a significant shareholder exits. The news of commercially interesting developments continues to broaden, meaning that substantial share price upside seems likely. Starpharma has a strong board ...

Previous 10 Next 10